Latest technology reporting
Evidence-led coverage of biotechnology, AI infrastructure, energy, robotics, devices and brain–computer interfaces.
-
AI Data Centre Water Use: What the Numbers Really Mean
AI data centre water use depends on cooling, climate and electricity supply. Explore company efficiency claims and the local figures communities need.
-
Commercial Fusion Power by the Mid-2030s? Inside the US Roadmap
The US fusion roadmap targets commercial power in the mid-2030s. Explore the materials, tritium, funding and engineering hurdles behind that ambition.
-
Optical AI Data Centre Networks: Why Lasers Are Replacing Copper
Explore how optical AI data centre networks move data, why co-packaged optics matters, and the power, reliability and cost trade-offs that remain.
-
AI Data Centre Liquid Cooling: Why Future Servers Need Plumbing
AI data centre liquid cooling moves heat from dense server racks. Learn how cold plates, warm water and facility design affect power and water use.
-
CRISPR Gene Therapy Approved for Children as Young as Two
Casgevy is approved from age two for sickle-cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassaemia. Learn the risks.
-
Pancreatic Cancer Prevention Vaccine Trains Immunity Before Disease
A small Phase 1 KRAS vaccine trial produced immune responses in people at inherited pancreatic cancer risk. It has not established cancer prevention.
-
Tiny CRISPR Could Unlock Gene Editing Inside the Body
A compact CRISPR enzyme could fit a complete editor into one AAV vector. Explore the preclinical research and unresolved delivery and safety questions.
-
Cholesterol Base Editing: Can One Infusion Replace Years of Treatment?
VERVE-102 lowered LDL in a small Phase 1b cholesterol base-editing trial. Explore the PCSK9 mechanism and why long-term safety and benefit remain unproven.
-
In Vivo CRISPR Gene Editing Passes Its First Phase 3 Test
Intellia reports fewer hereditary angioedema attacks in a Phase 3 lonvo-z trial. In vivo CRISPR still needs regulatory review and longer safety follow-up.
-
Partial Epigenetic Reprogramming Enters Human Trials
Partial epigenetic reprogramming has entered a Phase 1 eye-disease trial. Here is what ER-100 is testing, how OSK works and what remains unproven.
-
Off-the-Shelf CAR-T Reaches a Pivotal Leukaemia Trial
Off-the-shelf CAR-T candidate lasme-cel has entered a pivotal B-ALL trial after encouraging early responses. Here is how it works and why the evidence remains preliminary.
-
AI Data Centre Energy: The 1-Gigawatt Savannah River Plan
A proposed 1-gigawatt AI data centre at Savannah River would use about 2 gigawatts of on-site energy, starting with gas and moving toward nuclear.